- $28.57m
- $29.30m
- $1.27m
Brief: IGC Pharma Says Prior To Entering Agreement Terminated Sales Agreement Dated Jan 13, 2021
Brief: Igc Pharma Files For Offering Of 10 Million Shares Of Common Stock By Selling Stockholders
Brief: Igc Pharma - Continues To Make Significant Progress Advancing Lead Alzheimer's Candidate Through Phase 2 Clinical Trials
Brief: Igc Pharma Announces A $3 Mln Private Placement Of Its Common Stock
Brief: IGC Pharma Receives Notice Of Allowance For Patent On Seizures
Brief: Igc Announces Rebranding, Changes Name To Igc Pharma, Inc.
Brief: IGC Receives No Objection Letter From Health Canada
Brief: Igc Commences Phase 2 Clinical Trials Evaluating Drug Candidate Igc-Ad1 For The Treatment Of Agitation In Dementia From Alzheimer’S Disease
Brief: Igc Reports Results For Second Fiscal Quarter Ended Sept 30
Brief: IGC Reports Issuance Of Patent For Treatment Of Alzheimer’s Using THC
Brief: India Globalization Capital reports financial results for qtr ended June 30, 2022
India Globalization rises on deal for potential Alzheimer's treatment
Brief: IGC Acquires Exclusive Rights For A Potential Alzheimer's Drug Development Candidate
Brief: India Globalization Capital Appoints Claudia Grimaldi To Its Board Of Directors
Brief: India Globalization Capital Quarterly Loss Per Share $0.05
Brief: India Globalization Says Clinical Trial On Alzheimer’s Patients Indicates Positive Safety And Tolerability Data
Brief: Phase 1 Clinical Trial Data Indicate Igc’S Thc-Based Investigational New Drug May Reduce Symptoms Of Dementia In Alzheimer’S Patients
AMEX RESUMED INDIA GLOBLZN CP
AMEX HALT ADDITIONAL INFORMATION LAST 1.530000